| JAMA: Amgen Letter Submitted to the Editor |
| Cardiology Today: Cost-Effectiveness Model Greatly Exaggerates Costs of PCSK9 Inhibitors
|
| Stat: JAMA Report On Cholesterol Drugs Fails Reliability Test |
Medscape: Flawed JAMA Study Misrepresents Costs And Benefits Of New Cholesterol Drugs
|
USA Today: New cholesterol drugs could add $120 billion to annual U.S. health costs
|
